HYPERSECRETION OF TRUNCATED GLUCAGON-LIKE PEPTIDE-1 AND GASTRIC-INHIBITORY POLYPEPTIDE IN OBESE PATIENTS

被引：59

作者：

FUKASE, N ^{[1
]}

IGARASHI, M ^{[1
]}

TAKAHASHI, H ^{[1
]}

MANAKA, H ^{[1
]}

YAMATANI, K ^{[1
]}

DAIMON, M ^{[1
]}

TOMINAGA, M ^{[1
]}

SASAKI, H ^{[1
]}

机构：

[1] YAMAGATA UNIV,SCH MED,DEPT INTERNAL MED 3,2-2-2 IIDA NISHI,YAMAGATA 99023,JAPAN

来源：

DIABETIC MEDICINE | 1993年 / 10卷 / 01期

关键词：

GASTRIC INHIBITORY POLYPEPTIDE; TRUNCATED GLUCAGON-LIKE PEPTIDE-1; INCRETIN;

D O I：

10.1111/j.1464-5491.1993.tb01995.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Postprandial insulin secretion is modulated by both neural and humoral gastrointestinal insulinotropic factors in addition to the absorbed nutrient. To investigate the involvement of the potent insulinotropic hormones gastric inhibitory polypeptide (GIP) and truncated glucagon-like peptide-1 (tGLP-1) in the postprandial hyperinsulinaemia of obesity, we examined the changes in plasma levels of GIP and tGLP-1 by an oral glucose tolerance test (OGTT) in nine normal subjects (controls), nine obese subjects without glucose intolerance (Group A), and six obese mild diabetic patients (Group 8). Following the OGTT, plasma GIP levels in Group B were increased more markedly than those in the other two groups. Plasma levels of tGLP-1 were estimated by the difference between the values measured with the N-terminal directed antiserum (GLP-INT) and those with the C-terminal directed antiserum (GLP-1 CT). Plasma levels of GLP-1 NT were increased in Group B, but decreased in the other two groups. Plasma GLP-1 CT levels were increased in all groups with the highest response in Group B. These results suggest that the combined augmentation of plasma GIP and tGLP-1 responses were involved in the delayed and considerable increases in plasma insulin after glucose ingestion in obese diabetic patients. Since tGLP-1 is suppressed in the hyperglycaemic hyperinsulinaemic state in normal subjects, the augmented tGLP-1 response appears to be characteristic of obese Type 2 diabetes.

引用

页码：44 / 49

页数：6

共 33 条

[1] Assimacopoulos-Jeannet F, Jeanrenand B, The hormonal and metabolic basis of experimental obesity, Clinics in Endocrinology and Metabolism, 5, pp. 337-365, (1976)
[2] Reaven GM, Role of insulin resistance in human disease, Diabetes, 37, pp. 1595-1607, (1988)
[3] Zunz E, Labarre J, Contributions a l'étude des variations physiologiques de la secretion interne du pancreas: relations entre les secretions externe et interne du pancreas, Arch Int Physiol Biochim, 31, pp. 20-44, (1929)
[4] McIntyre N, Holdsworth DC, Turner DS, New interpretation of oral glucose tolerance, Lancet, 2, pp. 20-21, (1964)
[5] Brown JC, Dryburgh JR, Ross SA, Dupre J, Identification and actions of gastric inhibitory polypeptide, Recent Prog Horm Res, 31, pp. 487-532, (1975)
[6] Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC, Exon duplication and divergence in the human preproglucagon gen, Nature, 304, pp. 368-371, (1983)
[7] Heinrich G, Gros P, Lund PK, Bentley RC, Habener JF, Preproglucagon messenger ribonucleic acid: Nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acide, Endocrinology, 115, pp. 2176-2181, (1984)
[8] Bell GI, Santerre RF, Mullenbach GI, Hamster preproglucagon contains the sequence of glucagon and two related peptides, Nature, 302, pp. 712-718, (1983)
[9] Orskov C, Holst JJ, Kunthsen S, Baldissera FGA, Poulsen SS, Neilsen OV, Glucagon‐like peptide GLP‐1 and GLP‐2 predicted products of the glucagon gene are secreted separately from pig small intestine but not pancreas, Endocrinology, 119, pp. 1467-1475, (1986)
[10] Suda K, Manaka H, Takahashi H, Tominaga M, Sasaki H, The distribution and molecular forms of glucagon related peptides, Biomedical Res, 9, pp. 39-45, (1988)

← 1 2 3 4 →